ATRA Profile
Atara Biotherapeutics, Inc. is a biopharmaceutical company specializing in the development of advanced therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases. The company is focused on harnessing innovative immunotherapeutic approaches to address critical unmet medical needs in these challenging therapeutic areas.
Atara’s lead product, Tab-cel (tabelecleucel), represents a significant advancement in T-cell immunotherapy. Currently in Phase 3 clinical trials, Tab-cel is being evaluated for its efficacy in treating Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease and nasopharyngeal carcinoma. This therapy leverages engineered T-cells to target and eliminate EBV-infected cells, potentially offering a new treatment option for patients with these severe conditions.
The company’s CAR T-cell therapy pipeline includes several promising candidates. ATA2271 and ATA3271 are being developed to target mesothelin, a protein overexpressed in various cancers, while ATA3219 is focused on treating B-cell malignancies by targeting CD19. Additionally, ATA188, which is in Phase 2 clinical trials, aims to address multiple sclerosis through a novel approach that targets disease-related immune cells. These therapies reflect Atara’s commitment to advancing cutting-edge treatments across a range of oncology and autoimmune disorders.
Atara Biotherapeutics has established strategic partnerships to enhance its research and development capabilities. These include a license agreement with Memorial Sloan Kettering Cancer Center, a research and development collaboration with QIMR Berghofer Medical Research Institute, and a strategic collaboration with H. Lee Moffitt Cancer Center. Founded in 2012 and headquartered in Thousand Oaks, California, Atara Biotherapeutics continues to drive innovation in the field of immunotherapy, aiming to improve outcomes for patients with serious and difficult-to-treat conditions.
|
